Abstract: Objective To study the incidence of drug-induced liver injuries among inpatients at the Oncology Department of our hospital, summarize the clinical manifestations of liver damage, and evaluate the causality of drugs. Methods The medical history of drug-induced liver injuries that occurred in our hospital between January 2014 and December 2018 was retrospectively analyzed while the basic information of patients was recorded. The RUCAM score table was used to evaluate the causality of drug-induced liver injuries. Results A total of130 patients treated at the Department of Oncology of our hospital sustained drug-induced liver injuries, including 72 males and 58 females, with an average age of (64.4±10.71) years. The main clinical manifestations of liver injury were fatigue, yellowing of skin and mucous membrane, abdominal pain and anorexia. Sixty-four of these cases were of the cholestasis type, 20 cases of the hepatocyte damage type, and 46 cases were of the mixed type. Liver damage associated with chemotherapeutic agents was the most frequent with tegio, apatinib, capecitabine, oxaliplatin and cisplatin. Conclusion Drug-induced liver injury caused by chemotherapeutic drugs is one of the important causes of changes in the conditions of patients in the oncology department of internal medicine. Medical personnel should pay more attention to drug-induced liver injuries in the process of medical care.

Key words: drug-induced liver injury(DILI), chemotherapeutic agents, adverse drug reactions(ADRs), causality evaluation